secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001493152-25-017916
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharma reports Telomir-1 kills pancreatic cancer cells in vitro; plans further studies
--------------------------------------------------------------------------------

- Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in concentration-dependent manner.
- Effects partially reversed by iron re-addition, suggesting iron-dependent processes contribute to response.
- Telomir-1 previously shown to influence tumor suppressor genes and iron-dependent histone demethylases relevant to pancreatic cancer.
- Pancreatic cancer has five-year survival rate of ~12%; current treatments limited by toxicity and resistance.
- Telomir plans to expand preclinical research to leukemia models and initiate in vivo validation studies for IND preparation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225017916/0001493152-25-017916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225017916/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-017916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer